Search for: "Johnson v. Novartis Pharmaceuticals Corporation"
Results 1 - 18
of 18
Sorted by Relevance
|
Sort by Date
1 Mar 2011, 4:09 am
Novartis Pharmaceuticals Corp. v. [read post]
13 Jan 2018, 8:00 pm
” (Johnson v. [read post]
26 Feb 2010, 4:17 pm
Novartis Pharmaceuticals Corp.; Simonian v. [read post]
17 Jun 2010, 6:47 am
In its brief, the DOL argues that the district court in that case committed legal error when it concluded that the pharmaceutical sales representatives employed by Novartis Pharmaceutical Corporation (“NPC”) were exempt from the overtime requirements of the FLSA under the outsides sales and administrative exemptions. [read post]
18 Jun 2012, 1:38 pm
In the back of the Court’s mind, of course, was January’s $99 million settlement by Novartis for overtime claims by its pharmaceutical sales representatives following the Second Circuit’s 2010 decision in In re Novartis Wage & Hour Litig., and similar pending cases against Johnson & Johnson, Merck Co. and Bristol-Myers Squibb. [read post]
30 Jul 2010, 4:06 am
Jackson v. [read post]
10 Mar 2010, 5:22 am
Kappos (Patent Docs) US: New York Times provides soapbox for data exclusivity critics (Patent Docs) US: Massachusetts Institute of Technology dismissed as party in RNAi dispute: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e V et al v Whitehead Institute for Biomedical Research et al (Patent Docs) US: Cordis awarded fees and costs in surgical device suit: Marctec v Johnson & Johnson and Cordis Corporation (Patent Docs) US: Review… [read post]
10 Mar 2010, 5:22 am
Kappos (Patent Docs) US: New York Times provides soapbox for data exclusivity critics (Patent Docs) US: Massachusetts Institute of Technology dismissed as party in RNAi dispute: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e V et al v Whitehead Institute for Biomedical Research et al (Patent Docs) US: Cordis awarded fees and costs in surgical device suit: Marctec v Johnson & Johnson and Cordis Corporation (Patent Docs) US: Review… [read post]
2 Mar 2015, 2:43 pm
This one too is masterminded by Alan Johnson and Alexandria Palamountain.* Failure! [read post]
15 Oct 2008, 3:02 pm
The Supreme Court wil shortly hear these arguments in the context of a drug case and FDA preamble that attempts to grant immunity, when Wyeth v. [read post]
21 Dec 2012, 11:41 am
Johnson & Johnson, 48 A.3d 1041 (N.J. 2012). [read post]
12 Oct 2007, 7:03 am
Novartis Pharmaceuticals Corp., 2007 WL 2330713, at *4 (S.D. [read post]
25 Jul 2008, 7:04 am
, (Daily Dose of IP), 26 August: WIPO symposium on IP and multilateral agreements – Geneva: (IPKat), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop –… [read post]
4 Apr 2008, 1:00 am
- Counterfeit cash flooding the market: (Afro-IP), Debranded fakes for Liberia: an update: (Afro-IP), South African music industry blames pirates for falling sales of local artists: (Afro-IP), Plaintiff obtains interlocutory relief in patent case Sanitam Services Limited v Bins (Nairobi) Services Limited: (Afro-IP), South Africa – new patent judgments: Buckman Laboratories v Bromine Compounds; Northpark Trading 3 (Pty) Ltd v Ausplow (Pty) Ltd:… [read post]
13 Jun 2008, 3:40 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: ECJ rules trade mark holders cannot stop honest comparative advertising: O2 Holdings Limited and O2 (UK) Limited v Hutchinson 3G UK Limited: (Out-Law), (Catch Us If You Can!!!) [read post]
20 Jun 2008, 8:07 am
: (Spicy IP), Latin America: Merck Serono signs distribution agreement with Bristol-Myers Squibb for portfolio of established pharmaceutical brands in Latin America: (IP tango), US: Biotech industry growth to slow due to funding pressures and competition from biosimilars: (Managing Intellectual Property), US: House Commerce Committee posts responses to its questions on biogenerics; not surprisingly, the views run the gamut: (FDA Law Blog), US: Biosimilar debate heats up at BIO: (Managing… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
